Related Experiment Videos
Probucol reduces plasma lipid peroxides in man
J R Paterson1, A G Rumley, K G Oldroyd
1Institute of Biochemistry, Royal Infirmary, Glasgow, UK.
Atherosclerosis
|November 1, 1992
Summary
Probucol, a lipid-lowering drug, significantly reduces lipid peroxidation in hyperlipidaemic patients. This antioxidant effect, potentially via free radical scavenging, persists even after treatment cessation, suggesting a role in managing atherosclerosis progression.
Area of Science:
- Cardiovascular Pharmacology
- Oxidative Stress Research
Background:
- Probucol is a lipid-lowering agent with demonstrated antioxidant properties.
- Animal studies suggest probucol may inhibit or delay atherosclerosis progression, possibly by preventing low-density lipoprotein oxidation.
Purpose of the Study:
- To investigate the impact of probucol on free radical activity in hyperlipidaemic patients.
- To assess the duration of probucol's antioxidant effects.
Main Methods:
- Hyperlipidaemic patients received probucol treatment.
- Plasma lipid peroxides were measured at baseline, 4 weeks, 12 weeks, and 4 weeks post-treatment.
- Plasma vitamin E levels were also monitored.
Main Results:
- Significant reduction in plasma lipid peroxide concentrations during probucol treatment compared to baseline.
- Sustained reduction in lipid peroxides observed 4 weeks after discontinuing probucol.
- No significant changes in plasma vitamin E concentrations were noted.
Conclusions:
- Probucol effectively reduces lipid peroxidation in hyperlipidaemic patients.
- The observed antioxidant effect may be attributed to a free radical scavenging mechanism.
- These findings support probucol's potential therapeutic role in conditions associated with oxidative stress and atherosclerosis.